Chatillion, France, November 3, 2025DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer DBV ...

Châtillon, France, October 30, 2025DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Directors DBV ...

Châtillon, France, November 4, 2025 DBV Technologies to Participate in the Guggenheim 2nd Annual Healthcare Innovation ...

DBV Technologies (ENXTPA:DBV) remains unprofitable and is expected to stay in the red for at least the next three years. Over the past five years, the company has narrowed its losses at a rate of 5.9% ...

DBV Technologies, a French biotech working on a treatment for food allergies, says it's running out of cash. The disclosure came via a going concern note in the company’s fourth-quarter and full-year ...

DBV Technologies to Participate in Upcoming ACAAI 2025 Annual Scientific Meeting ...

Shares of the unique biotech DBV Technologies (NASDAQ: DBVT) surged nearly 20% higher on Wednesday, far outpacing many peer stocks. That's because the company had some very encouraging news to impart ...

H.C. Wainwright raised the firm’s price target on DBV Technologies (DBVT) to $20 from $16 and keeps a Buy rating on the shares following the Q3 ...

A recently announced partnership between global food giant Nestlé Group and DBV Technologies (DBVT), a France-based specialty biopharmaceutical company, is attracting investor attention for its focus ...

DBV Technologies has withdrawn the filing for FDA approval of its peanut allergy therapy. The French biotech pulled the BLA after talks with the agency revealed gaps in the manufacturing and ...

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of October 31, 2025 (Article 223-16 of the General Regulations of the Autorité des Marchés ...

DBV Technologies (DBVT) announced the appointment of Kevin Trapp as chief commercial officer, effective immediately. In his role, Trapp will ...